[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586173":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":19,"locations":25,"responsibleParty":43,"collaborators":47,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":11,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":11,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":11,"overallStatus":27,"whyStopped":11,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"University of Rochester","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"All participants","EXPERIMENTAL",null,[13],"Other: EEG measure of visual processing",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":11},"EEG measure of visual processing","Non-invasive scalp EEG measure of early cortical visual processing.",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":11,"email":24},"Edmund Lalor, PhD","CONTACT","585-275-3077","Edmund_Lalor@URMC.Rochester.edu",[26],{"facility":5,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"RECRUITING","Rochester","New York","14642","United States","US",{"type":34,"coordinates":35},"Point",[36,37],-77.61556,43.15478,{"lat":37,"lon":36},[40],{"name":21,"role":22,"phone":41,"phoneExt":11,"email":42},"585-3533824","Edmund_Lalor@urmc.rochester.edu",{"type":44,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Edmund Lalor","Associate Professor",[48],{"name":49,"class":50},"National Institute of Mental Health (NIMH)","NIH","100586173","visual-perception-in-schizophrenia-100586173",false,"NCT06911931","Visual Perception in Schizophrenia","Visual Perception in Schizophrenia: Assessing Predictive Processing in the Earliest Stages of the Visual Cortical Hierarchy","Inclusion Criteria:\n\n* All Subjects\n* Aged 18-65\n* 20\u002F32 visual acuity or better (using in-house optical correction, if necessary)\n* An ability to speak English well enough to complete study assessments and to consent to the study\n* Subjects with Schizophrenia-Spectrum Disorder\n* Meets DSM-5 diagnostic criteria for schizophrenia, schizoaffective disorder, or schizophreniform disorder as confirmed by the Structured Interview for DSM-5 (SCID-5).\n* Subjects with Bipolar Disorder\n* Meets DSM-5 diagnostic criteria for bipolar disorder (type I, II, or unspecified) as confirmed by the Structured Interview for DSM-5 (SCID-5).\n\nExclusion Criteria:\n\n* All subjects\n* Presence of characteristics that could impair one's ability to comprehend the nature of the study, provide informed consent, or understand the assessment questions, including the following:\n\n  * Subject cannot read and understand the instructions well enough to complete the tasks or cannot provide informed consent.\n  * Intellectual impairment (WRAT-5 score \\\u003C 70) (at the discretion of experimenter);\n  * Actively intoxicated, as shown via patient self-report or staff report;\n  * Substance use disorder in the past 3 months;\n  * Subject considered high risk for suicidal acts (i.e., active suicidal ideation as determined by clinical interview OR any suicide attempt in 30 days prior to screening);\n  * Subject violence (involving severe\u002Flethal means or violence occurring in prior 6 months) or extreme agitation.\n  * Being in a current manic state\n  * Head injury with loss of consciousness greater than 10 minutes (at the discretion of the experimenter).\n  * Subject has had electroconvulsive therapy (ECT) in the past 8 weeks;\n  * Diagnosed with a neurological condition (tumor, stroke, brain injury) or neurological disorder, including seizure disorders. Diagnosed with pervasive developmental disorder (phone screen or medical records)\n  * Lazy eye or squint or other known ocular pathology\n* Healthy Control Subjects\n* Any lifetime psychotic disorder or history of psychiatric hospitalization (self disclosure);\n* Daily antidepressant, mood stabilizer or antipsychotic medication use in the last 6 months, or benzodiazepine use during the prior 2 days (self-disclosure); iii. First-degree relative(s) with a schizophrenia spectrum disorder (based on subject self-report) or bipolar disorder.\n* Case-match Control Non-ill Subjects\n* Any lifetime psychotic disorder (as assessed by SCID\u002For SSD);\n* Recurrent depressive episodes or being in a current depressive episode (as assessed by SCID\u002For SSD)\n* Persistent threshold psychotic symptoms\n* History of psychiatric hospitalization;\n* Daily antidepressant, mood stabilizer or antipsychotic medication use in the last 6 months, or benzodiazepine use during the prior 2 days\n* First-degree relative(s) with a schizophrenia spectrum disorder (based on subject self-report) or bipolar disorder.\n* Bipolar Subjects\n* Persistent threshold psychotic symptoms",true,"ALL","18 Years","65 Years",{"count":63,"type":64},84,"ESTIMATED","INTERVENTIONAL",[67],"NA","This study aims to identify novel markers of psychosis using electroencephalography (EEG).",[70,71,72],"Schizophrenia Disorders","Bipolar Disorder","Schizo Affective Disorder","2025-11-10",{"date":75,"type":76},"2025-11-12","ACTUAL",{"date":78,"type":76},"2025-11-03",{"date":80,"type":64},"2027-01-31",{"name":5,"class":6},1]